Search
Menu
At IMB, we explore the molecular biology of the nucleus with an overarching focus on gene regulation, epigenetics & genome stability

University Medical Center (UMC) Mainz

Maria Felicia Basilicata  Christian Behl  Benedikt Berninger  Luciana Berod  Tobias Bopp  Andreas Daiber  Sven Danckwardt  Carsten Deppermann  Stephan Grabbe  Thomas Hofmann  Thomas Kindler  Daniela Kramer  Daniela Krause  Dilja Krueger-Burg  Michael Kühn  Beat Lutz  Johannes Mayer  Wolfram Ruf  Susann Schweiger  Natalia Soshnikova  Tim Sparwasser  Oliver Tüscher  Sara Vieira-Silva  Ari Waisman  Philipp Wild  Jennifer Winter  Fatemeh Zare-Shahneh 

Role of oncogenic signalling in epigenetics and DNA repair

In our laboratory, we are interested in understanding signal transduction pathways in cancer cells, with a focus on hematopoietic malignancies. A detailed understanding of aberrant signaling should provide insights into the process of malignant transformation, mechanisms of drug resistance and vulnerability of cancer cells. In addition, the identification of functional differences between cancer stem cells and their normal counterparts will allow us to develop novel therapeutic strategies. In this context we use a variety of distinct experimental approaches and tumor models, including cell culture, defined mouse models (e.g. Flt3-ITD knock-in, conditional KrasG12D knock-in, bone marrow transplantation) and primary tumor samples.

Research website

Positions held

  • Since 2009: Group Leader, University Medical Center (UMC), Mainz
  • Since 2009: Assistant Professor, University Medical Center (UMC), Mainz
  • Since 2008: Attending Physician, Department of Hematology and Oncology, University Medical Center (UMC), Mainz
  • 2005 - 2008: Postdoc, Harvard Medical School, Boston, USA

Education

  • 1994 - 1998: Medical Thesis, Institute of Immunology, Ludwig Maximilian University, Munich
  • 1997: Medical License, Ludwig Maximilian University, Munich

Selected publications by Thomas Kindler

Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, Kron B, Russo A, Lehmann N, Roth L, Fehr EM, Attig S, Hohberger A, Kindler T and Faber J (2017) CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis. J Immunother, 40(5):187-195

Sasca D, Hähnel PS, Szybinski J, Khawaja K, Kriege O, Pante SV, Bullinger L, Strand S, Strand D, Theobald M and Kindler T (2014) SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood, 124:121-133

Hähnel PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L, Theobald M and Kindler T (2014) Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy. Blood, 123:2355-2366

Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MA, Scadden DT, Schreiber SL, Ebert BL and Golub TR (2013) Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol, 9:840-848

Mercher T, Cornejo MG, Sears C, Kindler T, Moore SA, Aster JC and Gilliland DG (2008) Notch signaling specifies megakaryocyte development. Cell Stem Cell, 3, 314-326